Carolina Wealth Advisors LLC increased its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 68.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,741 shares of the company’s stock after purchasing an additional 7,626 shares during the quarter. AbbVie comprises about 1.8% of Carolina Wealth Advisors LLC’s holdings, making the stock its 12th largest position. Carolina Wealth Advisors LLC’s holdings in AbbVie were worth $4,716,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Ranch Capital Advisors Inc. lifted its stake in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Calamos Advisors LLC grew its stake in shares of AbbVie by 3.4% during the fourth quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after buying an additional 15,458 shares during the last quarter. Bingham Private Wealth LLC bought a new position in shares of AbbVie during the fourth quarter valued at about $1,147,000. Axecap Investments LLC increased its holdings in shares of AbbVie by 713.2% in the fourth quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock worth $3,729,000 after buying an additional 14,313 shares during the period. Finally, Legacy Edge Advisors LLC bought a new stake in shares of AbbVie in the 4th quarter valued at about $1,265,000. 70.23% of the stock is currently owned by institutional investors.
Key Headlines Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Apogee acquisition strengthens immunology pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, or $135.11 per share in cash. The deal adds zumilokibart, an investigational therapy for atopic dermatitis, asthma and other inflammatory diseases. Positive Phase 2 data support planned Phase 3 development, potentially helping AbbVie diversify its immunology portfolio and extend growth beyond existing products. The transaction is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
- Positive Sentiment: Botox Cosmetic could gain a fifth indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle condition associated with a wider facial appearance. FDA acceptance does not guarantee approval, but a new aesthetic use could expand Botox’s addressable market and support growth in one of AbbVie’s best-known brands. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
- Positive Sentiment: Analyst sentiment remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, and commentary following second-quarter results characterized ABBV as a potentially undervalued dividend and growth opportunity. AbbVie Receives Consensus Rating of Moderate Buy
- Neutral Sentiment: Strong operating performance is balanced by valuation: AbbVie’s latest quarter exceeded EPS and revenue expectations, with revenue rising 10.2% year over year, driven by SKYRIZI, RINVOQ and neuroscience products. However, the stock’s elevated P/E ratio leaves less room for execution or regulatory disappointments. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
- Negative Sentiment: Execution and deal risks remain: The Apogee transaction requires approvals and could bring integration costs and development risk if zumilokibart fails to reproduce its Phase 2 results in larger trials. AbbVie must also manage ongoing biosimilar pressure and sustain growth from its core immunology products.
AbbVie Price Performance
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period last year, the company earned $2.97 EPS. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.07 EPS for the current fiscal year.
AbbVie Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on ABBV. Wells Fargo & Company increased their target price on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, July 10th. Barclays boosted their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Canaccord Genuity Group lifted their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Morgan Stanley reissued an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.70.
Get Our Latest Research Report on AbbVie
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles
- Five stocks we like better than AbbVie
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
